Management of Stage 4 Large Cell Neuroendocrine Cancer
Diagnostic Approach
- The European Society for Medical Oncology recommends a multimodality imaging approach, including contrast-enhanced CT scan, MRI, and somatostatin receptor scintigraphy (SSRS) for detecting metastatic disease 1, 2
- Baseline tests should include chromogranin A (CgA) and 5-hydroxy indole acetic acid (5-HIAA), as well as additional tests such as thyroid function tests, parathyroid hormone, calcium, calcitonin, prolactin, alpha-fetoprotein, carcinoembryonic antigen (CEA), and beta-human chorionic gonadotrophin 2, 3
Treatment Options
- The National Comprehensive Cancer Network recommends platinum-based chemotherapy combined with etoposide as the standard first-line treatment for stage IV LCNEC 4
- For patients with large cell neuroendocrine carcinoma with poor differentiation, chemotherapy is strongly recommended, with alternative regimens considered based on molecular subtypes 2, 5
- Everolimus has shown activity in some neuroendocrine tumors, and may be considered in appropriate cases 6
Palliative Treatments
- Somatostatin analogs may be used for symptom control in patients with somatostatin receptor-positive tumors, and external beam radiotherapy can provide relief for bone pain from metastases 1, 2, 5, 6
- Ablative therapies may be considered for limited metastatic disease 6, 7
Prognosis
- Factors associated with worse prognosis include higher disease stage, poor performance status, presence of brain metastases, and high proliferation index 4